Abstract:A disease outbreak in December 2019, caused by a novel coronavirus SARS-CoV-2, was named COVID-19. SARS-CoV-2 infects cells from the upper and lower respiratory tract system and is transmitted by inhalation or contact with infected droplets. Common clinical symptoms include fatigue, fever, and cough, but also shortness of breath and lung abnormalities. Still, some 5% of SARS-CoV-2 infections progress to severe pneumonia and acute respiratory distress syndrome (ARDS), with pulmonary edema, acute kidney injury, and/or multiple organ failure as important consequences, which can lead to death. The innate immune system recognizes viral RNAs and triggers the expression of interferons (IFN). IFNs activate anti-viral effectors and components of the adaptive immune system by activating members of the STAT and IRF families that induce the expression of IFN-stimulated genes (ISG)s. Among other coronaviruses, such as Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV, common strategies have been identified to antagonize IFN signaling. This typically coincides with hyperactive inflammatory host responses known as the "cytokine storm" that mediate severe lung damage. Likewise, SARS-CoV-2 infection combines a dysregulated IFN response with excessive production of inflammatory cytokines in the lungs. This excessive inflammatory response in the lungs is associated with the local recruitment of immune cells that create a pathogenic inflammatory loop. Together, it causes severe lung pathology, including ARDS, as well as damage to other vulnerable organs, like the heart, spleen, lymph nodes, and kidney, as well as the brain. This can rapidly progress to multiple organ exhaustion and correlates with a poor prognosis in COVID-19 patients. In this review, we focus on the crucial role of different types of IFN that underlies the progression of SARS-CoV-2 infection and leads to immune cell hyper-activation in the lungs, exuberant systemic inflammation, and multiple organ damage. Consequently, to protect from systemic inflammation, it will be critical to interfere with signaling cascades activated by IFNs and other inflammatory cytokines. Targeting members of the STAT family could therefore be proposed as a novel therapeutic strategy in patients with severe COVID-19.

Specialized interferon action in COVID-19

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

A Commentary of “type I Interferon Deficiency Can Lead to Severe COVID-19” in 10 Remarkable Discoveries from 2020 in Nature

Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients

Differential Interferon-Α Subtype Induced Immune Signatures Are Associated with Suppression of SARS-CoV-2 Infection.

Serum Levels of Type I Interferon (IFN-I) is Associated with the Severity of COVID-19.

Harnessing the power of IFN for therapeutic approaches to COVID-19

Interferon gene expression declines over time post-COVID infection and in long COVID patients

Differential interferon-α subtype immune signatures suppress SARS-CoV-2 infection

The role of type I interferon in the treatment of COVID‐19

Longitudinal single cell atlas identifies complex temporal relationship between type I interferon response and COVID-19 severity

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Interferon‐α‐2b Aerosol Inhalation is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease‐2019

Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia

Role of interferons in the antiviral battle: from virus-host crosstalk to prophylactic and therapeutic potential in SARS-CoV-2 infection

Type-I interferon signatures in SARS-CoV-2 infected Huh7 cells

Interferon-stimulated genes and their antiviral activity against SARS-CoV-2

Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy

Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome

Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond

Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity